Wall Street analysts expect that Harvard Bioscience, Inc. (NASDAQ:HBIO – Get Rating) will report $0.03 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Harvard Bioscience’s earnings. Harvard Bioscience reported earnings of $0.06 per share in the same quarter last year, which would indicate a negative year over year growth rate of 50%. The firm is scheduled to issue its next earnings results on Monday, January 1st.
On average, analysts expect that Harvard Bioscience will report full-year earnings of $0.33 per share for the current fiscal year. For the next fiscal year, analysts expect that the business will report earnings of $0.40 per share. Zacks’ EPS averages are an average based on a survey of analysts that follow Harvard Bioscience.
Harvard Bioscience (NASDAQ:HBIO – Get Rating) last released its quarterly earnings results on Wednesday, May 4th. The medical instruments supplier reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.01). Harvard Bioscience had a positive return on equity of 9.06% and a negative net margin of 5.38%. During the same quarter in the prior year, the company earned $0.03 EPS.
In related news, CEO James W. Green acquired 10,000 shares of the firm’s stock in a transaction on Monday, May 9th. The shares were purchased at an average price of $3.40 per share, with a total value of $34,000.00. Following the acquisition, the chief executive officer now directly owns 2,319,955 shares in the company, valued at $7,887,847. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO James W. Green bought 30,000 shares of the business’s stock in a transaction on Friday, May 6th. The shares were acquired at an average price of $3.78 per share, for a total transaction of $113,400.00. Following the completion of the transaction, the chief executive officer now owns 2,309,955 shares in the company, valued at approximately $8,731,629.90. The disclosure for this purchase can be found here. Corporate insiders own 6.20% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. Marshall Wace LLP grew its stake in shares of Harvard Bioscience by 594.9% in the first quarter. Marshall Wace LLP now owns 86,543 shares of the medical instruments supplier’s stock valued at $373,000 after buying an additional 74,089 shares in the last quarter. SG Americas Securities LLC acquired a new position in Harvard Bioscience in the third quarter valued at about $103,000. Deutsche Bank AG raised its stake in Harvard Bioscience by 8.7% in the third quarter. Deutsche Bank AG now owns 24,931 shares of the medical instruments supplier’s stock valued at $174,000 after purchasing an additional 1,992 shares in the last quarter. Mackenzie Financial Corp acquired a new position in Harvard Bioscience in the third quarter valued at about $74,000. Finally, Barclays PLC raised its stake in Harvard Bioscience by 209.6% in the third quarter. Barclays PLC now owns 16,056 shares of the medical instruments supplier’s stock valued at $112,000 after purchasing an additional 10,870 shares in the last quarter. Hedge funds and other institutional investors own 72.75% of the company’s stock.
Shares of NASDAQ HBIO traded down $0.04 during midday trading on Friday, reaching $3.68. The company’s stock had a trading volume of 140,427 shares, compared to its average volume of 295,903. The company has a 50 day moving average price of $5.39 and a 200 day moving average price of $6.10. The company has a market cap of $151.76 million, a price-to-earnings ratio of -23.00 and a beta of 1.84. The company has a current ratio of 2.18, a quick ratio of 1.13 and a debt-to-equity ratio of 0.61. Harvard Bioscience has a one year low of $3.36 and a one year high of $8.75.
About Harvard Bioscience (Get Rating)
Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments.
- Get a free copy of the StockNews.com research report on Harvard Bioscience (HBIO)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.